Shiv Srivastava

List of Publications by Year
in descending order

52 papers	3,296 citations	279798 23 h-index	223800 46 g-index
54 all docs	54 docs citations	54 times ranked	3979 citing authors

#	Article	IF	Citations
1	Focal p53 protein expression and lymphovascular invasion in primary prostate tumors predict metastatic progression. Scientific Reports, 2022, 12, 5404.	3.3	10
2	Germline mutation landscape of DNA damage repair genes in African Americans with prostate cancer highlights potentially targetable RAD genes. Nature Communications, 2022, 13, 1361.	12.8	8
3	Prognostic features of Annexin A2 expression in prostate cancer. Pathology, 2021, 53, 205-213.	0.6	15
4	Abstract 2074: Germline mutation landscape of all DNA repair genes in African American prostate cancer patients. , 2021, , .		0
5	Abstract 2526: PMEPA1 gene isoforms indicated aggressive disease progression in non-prostate solid tumors. , 2021, , .		0
6	New Selective Inhibitors of ERG Positive Prostate Cancer: ERGi-USU-6 Salt Derivatives. ACS Medicinal Chemistry Letters, 2021, 12, 1703-1709.	2.8	5
7	A Germline Variant at 8q24 Contributes to Familial Clustering of Prostate Cancer in Men of African Ancestry. European Urology, 2020, 78, 316-320.	1.9	32
8	Detection of Head and Neck Cancer Based on Longitudinal Changes in Serum Protein Abundance. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1665-1672.	2.5	16
9	Increased frequency of germline BRCA2 mutations associates with prostate cancer metastasis in a racially diverse patient population. Prostate Cancer and Prostatic Diseases, 2019, 22, 406-410.	3.9	45
10	PMEPA1 gene isoforms to indicate disease progression in solid tumors.. Journal of Clinical Oncology, 2019, 37, e16580-e16580.	1.6	1
11	Increased Smad3 and reduced Smad2 levels mediate the functional switch of TGF-Î² from growth suppressor to growth and metastasis promoter through TMEPAI/PMEPA1 in triple negative breast cancer. Genes and Cancer, 2019, 10, 134-149.	1.9	24
12	Predicting Prostate Cancer Progression as a Function of ETS-related Gene Status, Race, and Obesity in a Longitudinal Patient Cohort. European Urology Focus, 2018, 4, 818-824.	3.1	16
13	Ethnicity and ERG frequency in prostate cancer. Nature Reviews Urology, 2018, 15, 125-131.	3.8	28
14	Prostate Cancer Genomics: Recent Advances and the Prevailing Underrepresentation from Racial and Ethnic Minorities. International Journal of Molecular Sciences, 2018, 19, 1255.	4.1	50
15	Re: Inherited DNA-repair Gene Mutations in Men with Metastatic Prostate Cancer. European Urology, 2017, 71, 692.	1.9	1
16	ETS Related Gene mediated Androgen Receptor Aggregation and Endoplasmic Reticulum Stress in Prostate Cancer Development. Scientific Reports, 2017, 7, 1109.	3.3	17
17	TMPRSS2:ERG Gene Fusions in Prostate Cancer of West African Men and a Meta-Analysis of Racial Differences. American Journal of Epidemiology, 2017, 186, 1352-1361.	3.4	60
18	Two Novel Susceptibility Loci for Prostate Cancer in Men of African Ancestry. Journal of the National Cancer Institute, 2017, 109, .	6.3	57

#	Article	IF	Citations
19	Autoantibodies against oncogenic ERG protein in prostate cancer: potential use in diagnosis and prognosis in a panel with C-MYC, AMACR and HERV-K Gag. Genes and Cancer, 2017, 7, 394-413.	1.9	14
20	Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer. Prostate, 2016, 76, 810-822.	2.3	45
21	Patient-specific Meta-analysis of 2 Clinical Validation Studies to Predict Pathologic Outcomes in Prostate Cancer Using the 17-Gene Genomic Prostate Score. Urology, 2016, 89, 69-75.	1.0	43
22	Loss of miR-449a in ERG-associated prostate cancer promotes the invasive phenotype by inducing SIRT1. Oncotarget, 2016, 7, 22791-22806.	1.8	19
23	Reconstitution of the ERG Gene Expression Network Reveals New Biomarkers and Therapeutic Targets in ERG Positive Prostate Tumors. Journal of Cancer, 2015, 6, 490-501.	2.5	4
24	A Biopsy-based 17-gene Genomic Prostate Score Predicts Recurrence After Radical Prostatectomy and Adverse Surgical Pathology in a Racially Diverse Population of Men with Clinically Low- and Intermediate-risk Prostate Cancer. European Urology, 2015, 68, 123-131.	1.9	281
25	ERG oncoprotein expression in prostate carcinoma patients of different ethnicities. Molecular and Clinical Oncology, 2015, 3, 23-30.	1.0	8
26	ERG Oncoprotein Inhibits ANXA2 Expression and Function in Prostate Cancer. Molecular Cancer Research, 2015, 13, 368-379.	3.4	12
27	Analytical platform evaluation for quantification of ERG in prostate cancer using protein and mRNA detection methods. Journal of Translational Medicine, 2015, 13, 54.	4.4	23
28	Silencing of PMEPA1 accelerates the growth of prostate cancer cells through AR, NEDD4 and PTEN. Oncotarget, 2015, 6, 15137-15149.	1.8	29
29	Methylation of thePMEPA1gene, a negative regulator of the androgen receptor in prostate cancer. Epigenetics, 2014, 9, 918-927.	2.7	25
30	A long noncoding RNA connects c-Myc to tumor metabolism. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 18697-18702.	7.1	258
31	Predominance of ERG-negative high-grade prostate cancers in African American men. Molecular and Clinical Oncology, 2014, 2, 982-986.	1.0	24
32	Functional antagonism of TMPRSS2-ERG splice variants in prostate cancer. Genes and Cancer, 2014, 5, 273-284.	1.9	8
33	Clinical potential of the ERG oncoprotein in prostate cancer. Nature Reviews Urology, 2012, 9, 131-137.	3.8	56
34	The center for prostate disease research (CPDR): A multidisciplinary approach to translational research. Urologic Oncology: Seminars and Original Investigations, 2009, 27, 562-569.	1.6	27
35	Identification of an Orphan 7TM Receptor PSGR as a Functional Intracellular GPCR. FASEB Journal, 2008, 22, 722.6.	0.5	0
36	Quantitative expression profile of androgen-regulated genes in prostate cancer cells and identification of prostate-specific genes. International Journal of Cancer, 2001, 92, 322-328.	5.1	96

#	Article	IF	Citations
37	A novel human cancer culture model for the study of prostate cancer. Oncogene, 2001, 20, 8036-8041.	5.9	31
38	p53-dependent induction of heat shock protein 27 (HSP27) expression. International Journal of Cancer, 2000, 88, 191-194.	5.1	21
39	Allelic loss on chromosome 6Q in primary prostate cancer. , 1999, 84, 331-335.		46
40	Effects of adenovirus-mediated p16INK4A expression on cell cycle arrest are determined by endogenous p16 and Rb status in human cancer cells. Oncogene, 1998, 16, 265-272.	5.9	115
41	Statistical Modeling Using Preoperative Prognostic Variables in Predicting Extracapsular Extension and Progression after Radical Prostatectomy for Prostate Cancer. Military Medicine, 1998, 163, 615-619.	0.8	12
42	Synchronous Bilateral Testicular Tumour: Nonseminomatous Germ Cell Tumours and Contralateral Benign Tumours. Scandinavian Journal of Urology and Nephrology, 1997, 31, 389-392.	1.4	24
43	Mutations of the p16 gene product are rare in prostate cancer. , 1997, 30, 188-194.		28
44	Biostatistical modeling using traditional variables and genetic biomarkers for predicting the risk of prostate carcinoma recurrence after radical prostatectomy. Cancer, 1997, 79, 952-962.	4.1	72
45	Inhibition of the growth of pre-established subcutaneous tumor nodules of human prostate cancer cells by single injection of the recombinant adenovirus p53 expression vector. , 1997, 71, 377-382.		46
46	Mutations of the p16 gene product are rare in prostate cancer. Prostate, 1997, 30, 188-194.	2.3	2
47	Biostatistical modeling using traditional variables and genetic biomarkers for predicting the risk of prostate carcinoma recurrence after radical prostatectomy. Cancer, 1997, 79, 952-962.	4.1	4
48	Inhibition of the growth of pre-established subcutaneous tumor nodules of human prostate cancer cells by single injection of the recombinant adenovirus p53 expression vector. , 1997, 71, 377.		1
49	Inhibition of the growth of preâ€established subcutaneous tumor nodules of human prostate cancer cells by single injection of the recombinant adenovirus p53 expression vector. International Journal of Cancer, 1997, 71, 377-382.	5.1	1
50	Elevated Levels of Apoptosis Regulator Proteins P53 and BCL-2 are Independent Prognostic Biomarkers in Surgically Treated Clinically Localized Prostate Cancer. Journal of Urology, 1996, 156, 1511-1516.	0.4	218
51	Alteration of the Tumor Suppressor Gene p53 in a High Fraction of Hormone Refractory Prostate Cancer. Journal of Urology, 1995, 154, 414-421.	0.4	161
52	Germ-line transmission of a mutated p53 gene in a cancer-prone family with Liâ€“Fraumeni syndrome. Nature, 1990, 348, 747-749.	27.8	1,156